14
Views
0
CrossRef citations to date
0
Altmetric
Original Research

Gender and secondary risk assessment following an ST-elevation myocardial infarction

, &
Pages 125-131 | Published online: 20 Aug 2013

References

  • Kushner FG, Hand M, Smith SC, et al. 2009 Focused Updates: ACC/AHA Guidelines for the Management of Patients with ST-Elevation Myocardial Infarction (updating the 2004 Guideline and 2007 Focused Update) and ACC/AHA/SCAI Guidelines for on Percutaneous Coronary Intervention (Updating the 2005 Guideline and 2007 Focused Update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2009;120:2271–2306.
  • American Heart Association. Heart Disease and Stroke Statistics: 2009 Update. Dallas: American Heart Association; 2009.
  • Roger VL, Go AS, Lloyd-Jones DM, et al. Heart disease and stroke statistics – 2012 update: a report from the AHA. Circulation. 2012;125: 188–197.
  • Keely EC, Boura JA, Grines CL. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomized trials. Lancet. 2003;361:13–20.
  • Rao SV Ohman EM. Anticoagulant therapy for percutaneous coronary intervention. Circ Cardiovasc Interv. 2010;3:80–88.
  • Rao SV Kaltenbach LA, Weintraub WS, et al. Prevalence and outcomes of same-day discharge after elective percutaneous coronary intervention among older adults. JAMA. 2011;13:1461–1467.
  • Lee KL, Woodlief LH, Topol EJ, et al. Predictors of 30-day mortality in the era of reperfusion for acute myocardial infarction. Results from an international trial of 41,021 patients. GUSTO-I Investigators. Circulation. 1995;91:1659–1668.
  • Fresco C, Sardinia F, Maggioni AP, et al. Very early assessment of risk for in-hospital death among 11,483 patients with acute myocardial infarction. GISSI Investigators. Am Heart J. 1999;138: 1058–1064.
  • Morrow DA, Antman EM, Charlesworth A, et al. TIMI risk score for ST-elevation myocardial infarction: a convenient, bedside, clinical score for risk assessment at presentation: an intravenous nPA for treatment of infarcting myocardium early II trial substudy. Circulation. 2000;102:2031–2037.
  • Morrow DA, Antman EM, Parsons L, et al. Application of the TIMI risk score for ST-elevation MI in the National Registry of Myocardial Infarction 3. JAMA. 2001;286:1356–1359.
  • Halkin A, Singh M, Nikolsky E, et al. Prediction of mortality after primary percutaneous coronary intervention for acute myocardial infarction. The CADILLAC risk score. J Am Coll Cardiol. 2005;45:1397–1405.
  • Granger CB, Goldberg RJ, Dabbous O, et al. Predictors of hospital mortality in the global registry of acute coronary events. Arch Intern Med. 2003;163:2345–2353.
  • Eagle, KA, Lim MJ, Dabbous OH, et al. A validated prediction model for all forms of acute coronary syndrome: estimating the risk of 6-month postdischarge death in an international registry. JAMA. 2004;291: 2727–2733.
  • Lev EI, Kornowski R, Vaknin-Assa H, et al. Comparison of the predictive value of four different risk scores for outcomes of patients with ST-elevation acute myocardial infarction undergoing primary percutaneous coronary intervention. Am J Cardiol. 2008;102:6–11.
  • Filipak KJ, Koltowski L, Grabowski M, et al. Prospective comparison of the 5 most popular risk scores in clinical use for unselected patients with acute coronary syndrome. Circ J. 2011;75(1):167–173.
  • Brkovic V, Dobric M, Beleslin B, et al. Additive prognostic value of the SYNTAX score over GRACE, TIMI, ZWOLLE, CADILLAC and PAMI risk scores in patients with acute ST-segment elevation myocardial infarction treated by primary percutaneous coronary intervention. Int J Cardiovasc Imaging. Epub February 27, 2013.
  • Scruth E, Cheng E, Worrall-Carter L. Risk score comparison of outcomes in patients presenting with ST-elevation myocardial infarction treated with percutaneous coronary intervention. Eur J Cardiovasc Nurs. Epub June 13, 2012.
  • Shaw LJ, Bairey Merz CN, Pepine CJ, et al. Insights from the NHLBI-Sponsored Women’s Ischemia Syndrome Evaluation (WISE) study: Part I: gender differences in traditional and novel risk factors, symptom evaluation, and gender-optimized diagnostic strategies. J Am Coll Cardiol 2006;47:S4–S20.
  • Pendyala LK, Torgoson R, Loh JP et al. Comparison of adverse outcomes after contemporary percutaneous coronary intervention in women versus men with acute coronary syndrome. Am J Cardiol. 2013;111: 1092–1098.
  • Norhammar A, Stenestrand U, Lindbäck J, Wallentin L. Women younger than 65 years with diabetes mellitus are a higher risk group after myocardial infarction: a report from the Swedish Register of Information and Knowledge about Swedish Heart Intensive Care Admission (RIKS-HIA). Heart. 2008:94;1565–1570.
  • Méndez-Eirín E, Flores-Ríos X, García-López F, et al. Comparison of the prognostic predictive value of the TIMI, PAMI, CADILLAC and GRACE Risk Scores in STEACS undergoing primary or rescue PCI. Rev Esp Cardiol. 2012;65:227–233.
  • Halkin A, Stone, GW, Dixon SR. Impact and determinants of left ventricular ejection fraction in patients undergoing primary percutaneous coronary intervention in acute coronary syndromes. Am J Cardiol. 2005;96:325–331.
  • Nikolsky E, Aymong ED, Halkin A, et al. Impact of anemia in patients with acute myocardial infarction undergoing percutaneous coronary intervention: analyses from the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial. J Am Coll Cardiol 2004;44:547–553.